Placeholder Banner

Cartier Esham’s Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases

July 30, 2021

BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families. I will highlight three such analyses with a focus on neurology clinical development programs (pipeline, investment and clinical trial success rates) with the goal of providing helpful insights to this important conversation. Later I will do a deeper dive into Alzheimer’s Disease as an example of the state of innovation for neurodegenerative diseases.

Download Full Comments Below
Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
Discover More
To meet the challenge of climate change, it is crucial to lead with science and U.S. innovation. We must incentivize the adoption of innovative, sustainable technologies and practices; and streamline and expedite regulatory pathways for breakthrough…
Safe, secure, affordable & accessible food supply Hundreds of millions of Americans and people around the world rely on safe and nutritious U.S. agricultural products and foods. Americans have access to one of the safest, most diverse, most…
BIO appreciates FDA’s commitment to harmonization of regulatory concepts across regional Health Authorities through the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). Harmonization of…